Zentalis Pharmaceuticals, Inc. PP&E Disclosure
| December 31, | |||||||||||
| 2024 | 2023 | ||||||||||
| Lab equipment | $ | 3,382 | $ | 3,069 | |||||||
| Leasehold improvements | 4,168 | 4,235 | |||||||||
| Office equipment and furniture | 1,280 | 1,340 | |||||||||
| Computer equipment | 143 | 150 | |||||||||
| Construction in process | — | 173 | |||||||||
| Subtotal | 8,973 | 8,967 | |||||||||
| Accumulated depreciation and amortization | (4,274) | (3,148) | |||||||||
| Property and equipment, net | $ | 4,699 | $ | 5,819 | |||||||
Want the next Zentalis Pharmaceuticals, Inc. pp&e disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Zentalis Pharmaceuticals, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 26, 2025 | Showing above |
| 2021 | Feb 24, 2022 | |
| 2020 | Mar 25, 2021 | |
About PP&E Disclosures
The PP&E disclosure details a company's physical asset base — land, buildings, machinery, and equipment — along with the depreciation methods and useful life assumptions that determine how these costs flow through the income statement. Capitalization policy thresholds reveal management's judgment on the boundary between expense and asset, directly affecting both reported earnings and asset values.
Key signals: changes in estimated useful lives or depreciation methods can materially shift reported earnings without any operational change. Compare capital expenditures against depreciation expense — when capex consistently trails depreciation, the asset base may be aging and underinvested. Watch for large asset impairments or write-downs that signal overvalued carrying amounts. Asset retirement obligations reveal future environmental or decommissioning costs that are often underappreciated. Compare PP&E intensity (PP&E-to-revenue) against industry peers to assess capital efficiency and competitive positioning.